Abeona Therapeutics Inc (NASDAQ: ABEO) Phase 1 / 2 Transpher A-Data Published
Abeona Therapeutics Inc (NASDAQ: ABEO) is an integrated player in gene therapy. It announced the MRI (Magnetic Resonance Imaging) data from its Phase 1 /2 Transhper A clinical study indicating an increase of grey matter in patients at 24 months compared to the patient without treatment. New data published: As per the company, MRI (Magnetic Resonance Imaging) data indicates ABO-102 led to an uptick in grey matter, amygdala volumes, and…